Clinical Trial Goal
To find out:
- The highest dose of docirbrutinib that’s safe to give
- If docirbrutinib is safe and works well to treat B-NHL, CLL, or SLL that has relapsed or is refractory
You may be able to join this trial if you:
- Are 18 years old or older
- Have one of the following that is relapsed or refractory:
- B-NHL. Some examples include:
- Follicular lymphoma
- Mantle cell lymphoma (MCL)
- Marginal zone lymphoma (MZL)
- Waldenström macroglobulinemia
- CLL
- SLL
- B-NHL. Some examples include:
- Do not have Richter's transformation. Your doctor can tell you this
- Do not have untreated lymphoma in your brain or spinal cord
- Agree to have other standard tests done to see if you can be in the clinical trial
Trial Details
Docirbrutinib is a small molecule inhibitor that blocks BTK in certain cells.
You’ll get treatment in cycles that last 1 month. In each cycle, you'll get:
You’ll get treatment in cycles that last 1 month. In each cycle, you'll get:
- Docirbrutinib – A pill that you take by mouth 2 times each day. The dose you'll get depends on when you start the trial and how safe it has been
You may continue treatment for as long as the clinical trial for as long as the doctor thinks it best for your health. You'll have biopsies and/or scans to see how well the treatment is working. The clinical trial doctors will check your health for up to 2 years.
The Food and Drug Administration (FDA) has approved has not yet approved docirbrutinib.
Locations
Sponsors
lead: Carna Biosciences, Inc.
